Back

Do CYP2D6 polymorphisms affect the efficacy and toxicity of flecainide? A cohort study.

1 September 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Rhythm control in atrial fibrillation: prognostic and therapeutic implications Rhythm Control, Antiarrhythmic Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Mauro Trincado Ave

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

8 More presentations in this session

Presentation thumbnail
Cluster-specific predictors of early rhythm control in contemporary European cohort of patients with atrial fibrillation: The EHRA-PATHS Project
Doctor M. Mihajlovic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Impact of rhythm control strategy on outcomes in patients with first diagnosed atrial fibrillation in an 11-year real-world registry
Doctor C. Salbach (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Atrial function after cardioversion in patients with persistent atrial fibrillation
Doctor K. Noda (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Sinus rhythm maintenance and the changes of echocardiographic parameters in patients with late persistent atrial fibrillation at 6 months after direct current cardioversion
Doctor Y. Skybchyk (Kiev, UA)
Abstract Slides Video
Presentation thumbnail
H558R: a common polymorphism may modify the efficacy and toxicity of flecainide in maintaining sinus rhythm; a cohort study.
Mr M. Trincado Ave (Santiago de Compostela, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Rhythm control in atrial fibrillation: prognostic and therapeutic implications

The Event

Event poster

ESC Congress 2024

1 September 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Joint relevance of CYP2D6 and H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study.
thumbnail
Congress Presentation
H558R: a common polymorphism may modify the efficacy and toxicity of flecainide in maintaining sinus rhythm; a cohort study.
thumbnail
Congress Session
Pharmacogenetics: a tool to guide clinical decisions

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources